Sydney, Australia – March 3rd, 2025 – InMode Australia is proud to announce the
showcasing of ASCE+ Exosomes by ExoCoBio at IMCAS Paris 2025, highlighting the latest
advancements in regenerative aesthetics. As the global leader in exosome science, ExoCoBio
presented revolutionary research and real-world applications of ASCE+ Exosomes for skin and hair
rejuvenation.
ASCE+ Exosomes treatments are founded on cutting-edge biotechnology breakthroughs for skin and
scalp rejuvenation and regeneration. Clinically proven and award-winning, ASCE+ Exosomes are key
players in cell-to-cell communication, facilitating the exchange of RNA, proteins, growth factors,
cytokines, and genetic materials between various cell types, including fibroblasts, keratinocytes, and
immune cells. This exchange is critical for tissue repair and the enhancement of skin cells.
InMode Australia and ExoCoBio, a leading cosmeceutical and biopharmaceutical company based in
Korea, have joined forces to introduce cutting-edge exosome solutions to the Australian and New
Zealand markets. ExoCoBio is a distinguished leader in the field of exosome research, development,
and manufacturing. With a dedication to advancing regenerative medicine and life sciences, it has
garnered international recognition for its cutting-edge exosome products. This collaboration marks a
significant milestone in the healthcare and aesthetics industry.
At IMCAS Paris 2025, ExoCoBio was officially recognised as the only exosome company that has
conducted human studies, solidifying its position as the leader in exosome science. Additionally, with
over 100 patents, ExoCoBio is further demonstrating its commitment to innovation and scientific
excellence.
ASCE+ Exosomes have been honoured with the AMWC 2024 Aesthetic Medicine Award for Best
Regenerative Aesthetic Medicine Product, underscoring their transformative impact on the industry.
InMode Australia is excited to bring these innovative treatments to the forefront of the aesthetic
industry, offering practitioners and patients access to the most scientifically validated exosome
technology available.
